AQR Capital Management
ALXO icon

AQR Capital Management’s ALX Oncology ALXO Stock Holding History

AQR Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,793
Closed -$19.8K – 3567
2025
Q3 		$19.8K Sell
10,793
-34,790
-76% -$30.1K ﹤0.01% 3449
2025
Q2 		$18.9K Sell
45,583
-73,467
-62% -$37.1K ﹤0.01% 3286
2025
Q1 		$74.2K Buy
119,050
+77,065
+184% +$92.5K ﹤0.01% 3056
2024
Q4 		$70.1K Buy
41,985
+13,479
+47% +$20.7K ﹤0.01% 2793
2024
Q3 		$51.9K Buy
28,506
+10,427
+58% +$38.8K ﹤0.01% 2703
2024
Q2 		$109K Buy
18,079
+6,080
+51% +$74.8K ﹤0.01% 2487
2024
Q1 		$134K Buy
+11,999
New +$169K ﹤0.01% 2309

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

AQR Capital Management's ALXO Position: Q4 2025 in Review

AQR Capital Management sold out of ALX Oncology (ALXO) in Q4 2025, closing a stake of 10,793 shares — an estimated $19.8K sold.

AQR Capital Management first reported a position in ALXO in Q1 2024 and held it in 7 quarters. The position peaked at $134K in Q1 2024. 57 funds tracked by Wall St. Rank hold ALXO as of Q4 2025.

  • AQR Capital Management reported no remaining ALX Oncology position as of Q4 2025 after selling out during the quarter.
  • AQR Capital Management sold 10,793 ALX Oncology shares in Q4 2025, an estimated $19.8K.
  • AQR Capital Management first reported a position in ALX Oncology in Q1 2024 and held it in 7 quarters.
  • AQR Capital Management's ALX Oncology position peaked at $134K in Q1 2024.
  • 57 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2025.

Based on AQR Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.